458 related articles for article (PubMed ID: 27716592)
1. Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases.
Kandula M; Sunil Kumar KB; Palanichamy S; Rampal A
Int Immunopharmacol; 2016 Nov; 40():443-451. PubMed ID: 27716592
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis.
Jung Y; Kim HH; Kim H; Kong H; Choi B; Yang Y; Kim Y
Eur J Pharm Sci; 2006 May; 28(1-2):26-33. PubMed ID: 16455235
[TBL] [Abstract][Full Text] [Related]
3. Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease.
Dhaneshwar SS
World J Gastroenterol; 2014 Apr; 20(13):3564-71. PubMed ID: 24707139
[TBL] [Abstract][Full Text] [Related]
4. Design and development of novel azo prodrugs using various permutations and combinations of 5- and 4-aminosalicylic acids for inflammatory bowel disease: a colon-targeted approach.
Suneela D; Gaurav V; Himanshu R
Inflamm Allergy Drug Targets; 2013 Oct; 12(5):328-40. PubMed ID: 24001333
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Evaluation of 5-ASA Colon-Specific Tablets Using Experimental-Induced Colitis Rat Animal Model.
Sawarkar SP; Deshpande SG; Bajaj AN; Nikam VS
AAPS PharmSciTech; 2015 Dec; 16(6):1445-54. PubMed ID: 26017284
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice.
Sann H; Erichsen Jv; Hessmann M; Pahl A; Hoffmeyer A
Life Sci; 2013 Apr; 92(12):708-18. PubMed ID: 23399699
[TBL] [Abstract][Full Text] [Related]
7. 5-Aminosalicylic Acid Azo-Coupled with a GPR109A Agonist Is a Colon-Targeted Anticolitic Codrug with a Reduced Risk of Skin Toxicity.
Jeong S; Lee H; Kim S; Ju S; Kim W; Cho H; Kim HY; Heo G; Im E; Yoo JW; Yoon IS; Jung Y
Mol Pharm; 2020 Jan; 17(1):167-179. PubMed ID: 31743034
[TBL] [Abstract][Full Text] [Related]
8. Validation of a pharmacokinetic model of colon-specific drug delivery and the therapeutic effects of chitosan capsules containing 5-aminosalicylic acid on 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats.
Tozaki H; Fujita T; Odoriba T; Terabe A; Okabe S; Muranishi S; Yamamoto A
J Pharm Pharmacol; 1999 Oct; 51(10):1107-12. PubMed ID: 10579681
[TBL] [Abstract][Full Text] [Related]
9. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.
Kimura I; Kawasaki M; Nagahama S; Matsuda A; Kataoka M; Kokuba Y
Arzneimittelforschung; 1998 Nov; 48(11):1091-6. PubMed ID: 9850431
[TBL] [Abstract][Full Text] [Related]
10. [New salicylic acid derivatives in the treatment of inflammatory intestinal diseases].
Kovács A
Orv Hetil; 1991 Jun; 132(24):1317-21. PubMed ID: 1677465
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic efficacy of 5-ASA molecules in idiopathic intestinal inflammatory diseases: critical review].
Van Gossum A
Acta Gastroenterol Belg; 1992; 55(5-6):462-71. PubMed ID: 1363167
[TBL] [Abstract][Full Text] [Related]
12. 5-Aminosalicylic Acid Azo-Linked to Procainamide Acts as an Anticolitic Mutual Prodrug via Additive Inhibition of Nuclear Factor kappaB.
Kim W; Nam J; Lee S; Jeong S; Jung Y
Mol Pharm; 2016 Jun; 13(6):2126-35. PubMed ID: 27112518
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
Dhaneshwar SS; Gairola N; Kandpal M; Vadnerkar G; Bhatt L; Rathi B; Kadam SS
Eur J Med Chem; 2009 Oct; 44(10):3922-9. PubMed ID: 19442419
[TBL] [Abstract][Full Text] [Related]
14. A colon-specific prodrug of metoclopramide ameliorates colitis in an experimental rat model.
Yang Y; Kim W; Kim D; Jeong S; Yoo JW; Jung Y
Drug Des Devel Ther; 2019; 13():231-242. PubMed ID: 30643389
[TBL] [Abstract][Full Text] [Related]
15. Colon-specific, mutual azo prodrug of 5-aminosalicylic acid with L-tryptophan: synthesis, kinetic studies and evaluation of its mitigating effect in trinitrobenzenesulfonic acid-induced colitis in rats.
Dhaneshwar SS; Gairola N; Kandpal M; Vadnerkar G; Bhatt L
Bioorg Med Chem; 2007 Jul; 15(14):4903-9. PubMed ID: 17499512
[TBL] [Abstract][Full Text] [Related]
16. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
[TBL] [Abstract][Full Text] [Related]
17. Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience.
Tolia V; Massoud N; Klotz U
J Pediatr Gastroenterol Nutr; 1989 Apr; 8(3):333-8. PubMed ID: 2565380
[TBL] [Abstract][Full Text] [Related]
18. Dextran-5-(4-ethoxycarbonylphenylazo)salicylic acid ester, a polymeric colon-specific prodrug releasing 5-aminosalicylic acid and benzocaine, ameliorates TNBS-induced rat colitis.
Nam J; Kim W; Lee S; Jeong S; Yoo JW; Kim MS; Jung Y
J Drug Target; 2016; 24(5):468-74. PubMed ID: 26377354
[TBL] [Abstract][Full Text] [Related]
19. Comparison of prostaglandin E2 receptor subtype 4 agonist and sulfasalazine in mouse colitis prevention and treatment.
Jiang GL; Im WB; Donde Y; Wheeler LA
J Pharmacol Exp Ther; 2010 Dec; 335(3):546-52. PubMed ID: 20833794
[TBL] [Abstract][Full Text] [Related]
20. Newer pharmacologic agents for the therapy of inflammatory bowel disease.
Ruderman WB
Med Clin North Am; 1990 Jan; 74(1):133-53. PubMed ID: 2404172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
